drugset
drugset / Trial / NCT02005120

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

NCT02005120 ↗

Phase 2 Unknown 20 enrolled Zhejiang University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. The other widely used treatment for MPE is recombinant human endostatin.

Timeline

Start
2013-12
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — Other
Subject Endostar Protein / enzyme biologic — Other

Indications

non-small cell lung carcinoma